免疫检查点抑制剂与类风湿关节炎:条条大路通向PD-1?
本文综述PD-1/PD-L1及CTLA-4等免疫检查点分子在类风湿关节炎(RA)中的双向调控意义:PD-1激动剂正被开发用于治疗RA,而抗PD-1/PD-L1抑制剂可能用于合并癌症的RA患者,且免疫检查点抑制剂治疗中可新发炎症性关节炎并转诊风湿科。三种临床情景均存诸多未解问题,PD-1/PD-L1通路双向药物的并行研发为炎症性关节炎研究提供了独特发现机会。
要点
- PD-1激动剂正被开发用于治疗类风湿关节炎。
- 合并癌症的类风湿关节炎患者可能接受抗PD-1/PD-L1免疫检查点抑制剂治疗。
- 免疫检查点抑制剂治疗中可新发炎症性关节炎并转诊风湿科管理。
核心结论
- PD-1/PD-L1通路双向调控在类风湿关节炎中仍有诸多未解临床与转化问题,同时拮抗与激动该通路的药物并行研发为炎症性关节炎研究提供了独特发现机会。
研究设计与样本
- 本文为综述,围绕PD-1、PD-L1及CTLA-4等免疫检查点分子在类风湿关节炎中的双向调控进行论述。
主要发现
- PD-1激动剂正被开发用于治疗类风湿关节炎;抗PD-1/PD-L1免疫检查点抑制剂可用于合并癌症的类风湿关节炎患者;免疫检查点抑制剂治疗中可新发炎症性关节炎并转诊风湿科。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint molecules like PD-1 and its ligand PD-L1 and CTLA-4 are important regulators of the immune system. Medications blocking these pathways, immune checkpoint inhibitors, have been used to treat a variety of malignancies, while drugs agonizing these pathways, like abatacept, have been used in treating autoimmune diseases. Modulation of the PD-1/PD-L1 axis has become important for rheumatologists to understand in several different clinical scenarios. Currently, PD-1 agonists are being developed for treatment of rheumatoid arthritis (RA). In addition to patients with RA being potentially treated with PD-1 agonists, patients with rheumatoid arthritis may be treated with anti-PD-1/PD-L1 immune checkpoint inhibitors if they develop cancer. Finally, patients treated with immune checkpoint inhibitors may develop de novo inflammatory arthritis and be referred to rheumatology for management. In all three scenarios, there remain many unanswered clinical and translational questions. The parallel development of therapeutics antagonizing and agonizing the PD-1/PD-L1 pathway presents a unique chance for discovery in inflammatory arthritis.
引用
- Cappelli LC. Immune checkpoint inhibitors and rheumatoid arthritis: All roads lead to PD-1? Semin Arthritis Rheum. 2024. PMID: 39578183. doi:10.1016/j.semarthrit.2024.152582
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。